Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of praziquantel in resisting renal fibrosis diseases

A technology of renal fibrosis and praziquantel, applied in the field of biomedicine, to reduce the degree of renal fibrosis and improve renal function

Pending Publication Date: 2022-07-29
NANJING MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether praziquantel also has a reversal effect on renal fibrosis, there is no relevant evaluation data

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of praziquantel in resisting renal fibrosis diseases
  • Application of praziquantel in resisting renal fibrosis diseases
  • Application of praziquantel in resisting renal fibrosis diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Preparation of Praziquantel Suspension

[0034] ①1% carboxymethyl cellulose solution: accurately weigh 1g of carboxymethyl cellulose powder on an analytical balance and dissolve it in 100mlddH 2 O, fully shake with a vortexer, place it on a shaker in a 4°C refrigerator overnight to prepare a transparent 1% carboxymethyl cellulose solution, and store it on a 4°C refrigerator shaker for one week.

[0035] ② Praziquantel suspension: Accurately weigh an appropriate amount of praziquantel powder with an analytical balance, mix thoroughly with a 1% carboxymethyl cellulose solution, and prepare a praziquantel suspension with a concentration of 300 mg / kg, which can be stored in a refrigerator at 4°C. Save for a week.

Embodiment 2

[0036] Example 2 Treatment of praziquantel against renal fibrosis in mice infected with Schistosoma japonicum in chronic phase

[0037]Mice infected with Schistosoma japonicum for 10 weeks (in the chronic phase of infection) and normal mice were randomly divided into groups of 6-8 mice in each group. The anti-fibrotic dose of praziquantel was administered in two ways: oral gavage and intramuscular injection. The specific grouping and treatment methods are as follows: ①Normal control group (Normal): normal mice; ②Normal oral administration of praziquantel group [Normal+PZQ(ig)]: During the same period, normal mice were orally administered 100 μl of praziquantel at a concentration of 300 mg / kg Oral administration, once every 12 hours; ③ Normal intramuscular injection of praziquantel group [Normal+PZQ(im)]: In the same period, normal mice were injected with 20% concentration of praziquantel at a concentration of 300 mg / kg, 300 μl leg intramuscular injection, every 12 Once an hou...

Embodiment 3

[0038] Example 3 Detection of renal appearance and renal function in mice treated with praziquantel for anti-fibrosis

[0039] ①Urine protein content semi-quantitative: Collect the morning urine of mice, drop it evenly on the detection area of ​​the test strip, absorb the excess urine with a paper towel after 2 seconds, compare it with the standard colorimetric card within 60-120 seconds, and complete the colorimetric Photograph.

[0040] ②Detection of serum creatinine level: After the mice were anesthetized, blood was collected from the medial canthal vein to separate the serum. The serum creatinine level of each sample was detected by Olympus AU5400 automatic biochemical analyzer.

[0041] The application result of the present invention shows: compared with the infection group, the renal function index urine protein content and serum creatinine level of the mice in the administration group decreased after 14 days of administration, and basically returned to the normal group ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of praziquantel in resisting renal fibrosis diseases, and relates to the field of biomedicine. By applying praziquantel, collagen deposition caused by schistosome infection can be reduced, and high-expression connective tissue growth factors (CTGF) and collagen molecules Col1, Col3 and Col4 in kidney tissues are reversed, so that the lesion of renal fibrosis is improved; the praziquantel disclosed by the invention has a good application prospect of resisting renal fibrosis diseases.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of praziquantel in anti-renal fibrosis diseases. Background technique [0002] Kidney disease affects approximately 10% of the world's population and is a pressing global health problem. Renal fibrosis (renal fibrosis) is the common basis of renal disease eventually leading to end-stage renal failure. Diseases that lead to renal fibrosis include diabetes, hypertension, systemic lupus erythematosus, chronic glomerulonephritis, chronic pyelonephritis, drugs and infectious diseases. The kidney is stimulated by various pathogenic factors such as trauma, infection, inflammation, blood circulation disorder, and immune response, the persistent inflammatory environment and abnormal tissue repair cause a large amount of extracellular matrix accumulation, which occurs in the glomerulus and renal tubules. It is mainly qualitative, and eventually progresses to renal fibrosis, whi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4985A61K45/06A61P13/12
CPCA61K31/4985A61K45/06A61P13/12A61K2300/00
Inventor 王勇赵成思刘新建张戎
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com